(19)
(11) EP 2 861 608 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.06.2019 Bulletin 2019/25

(45) Mention of the grant of the patent:
24.04.2019 Bulletin 2019/17

(21) Application number: 13806968.7

(22) Date of filing: 19.06.2013
(51) International Patent Classification (IPC): 
C07F 9/6561(2006.01)
A61P 31/04(2006.01)
 A61K 31/675(2006.01)
C07F 9/60(2006.01)
(86) International application number:
PCT/IB2013/001780
(87) International publication number:
WO 2013/190384 (27.12.2013 Gazette 2013/52)

(54)

PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE

PRODRUG-DERIVATE VON (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL) METHYL)-3- (7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMID

DÉRIVÉS DE TYPE PROMÉDICAMENT DU (E)-N-MÉTHYL-N-((3-MÉTHYLBENZOFURAN-2-YL) MÉTHYL)-3-(7-OXO-5,6,7,8-TÉTRAHYDRO-L,8-NAPHTYRIDIN-3-YL)ACRYLAMIDE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 19.06.2012 US 201261661559 P

(43) Date of publication of application:
22.04.2015 Bulletin 2015/17

(73) Proprietor: Debiopharm International SA
1006 Lausanne (CH)

(72) Inventors:
  • PARTRIDGE, John, J.
    Chapel Hill, NC 27516-6832 (US)
  • COLUCCI, John
    Kirkland, QC H9K 1S2 (CA)
  • GAREAU, Yves
    Notre-Dame de L'ile-Perrot, QC J7V 7P2 (CA)
  • THERIEN, Michel
    Laval, QC H7R 4R2 (CA)
  • ZAMBONI, Robert
    Beaconsfield, QC H9W 5L4 (CA)
  • HAFKIN, Barry
    Austin, TX 78755 (US)
  • MARFAT, Anthony
    Mystic, CT 06355 (US)
  • ZAGHDANE, Helmi
    Pincourt, Québec J7W 0B9 (CA)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
WO-A1-2008/098374
CA-A1- 2 776 849
 WO-A1-2010/151689
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).